|Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer|
EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ...
New England Journal of Medicine 363 (18), 1693-1703, 2010
|Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK|
AT Shaw, BY Yeap, M Mino-Kenudson, SR Digumarthy, DB Costa, ...
Journal of clinical oncology 27 (26), 4247, 2009
|Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer|
AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, ...
New England Journal of Medicine 371 (21), 1963-1971, 2014
|Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study|
DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ...
The lancet oncology 13 (10), 1011-1019, 2012
|Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints|
S Koyama, EA Akbay, YY Li, GS Herter-Sprie, KA Buczkowski, ...
Nature communications 7 (1), 10501, 2016
|Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis|
AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ...
The lancet oncology 12 (11), 1004-1012, 2011
|Clinical experience with crizotinib in patients with advanced ALK-rearranged non–small-cell lung cancer and brain metastases|
DB Costa, AT Shaw, SHI Ou, BJ Solomon, GJ Riely, MJ Ahn, C Zhou, ...
Journal of Clinical Oncology 33 (17), 1881, 2015
|CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib|
DB Costa, S Kobayashi, SS Pandya, WL Yeo, Z Shen, W Tan, KD Wilner
Journal of Clinical Oncology 29 (15), e443-e445, 2011
|BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations|
DB Costa, B Halmos, A Kumar, ST Schumer, MS Huberman, TJ Boggon, ...
PLoS medicine 4 (10), e315, 2007
|EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications|
H Yasuda, S Kobayashi, DB Costa
The lancet oncology 13 (1), e23-e31, 2012
|Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancers dependent on the epidermal growth factor receptor pathway|
KSH Nguyen, S Kobayashi, DB Costa
Clinical lung cancer 10 (4), 281-289, 2009
|RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer|
MJ Niederst, LV Sequist, JT Poirier, CH Mermel, EL Lockerman, ...
Nature communications 6 (1), 6377, 2015
|Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–positive lung cancer and acquired resistance to osimertinib|
GR Oxnard, Y Hu, KF Mileham, H Husain, DB Costa, P Tracy, N Feeney, ...
JAMA oncology 4 (11), 1527-1534, 2018
|A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response|
Z Chen, K Cheng, Z Walton, Y Wang, H Ebi, T Shimamura, Y Liu, ...
Nature 483 (7391), 613-617, 2012
|Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer|
H Yasuda, E Park, CH Yun, NJ Sng, AR Lucena-Araujo, WL Yeo, ...
Science translational medicine 5 (216), 216ra177-216ra177, 2013
|Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer|
LV Sequist, J Von Pawel, EG Garmey, WL Akerley, W Brugger, D Ferrari, ...
J Clin Oncol 29 (24), 3307-3315, 2011
|Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers|
D Rangachari, N Yamaguchi, PA VanderLaan, E Folch, A Mahadevan, ...
Lung cancer 88 (1), 108-111, 2015
|Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or ErlotinibCNS …|
S Heon, BY Yeap, GJ Britt, DB Costa, MS Rabin, DM Jackman, ...
Clinical cancer research 16 (23), 5873-5882, 2010
|Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014|
BJ Solomon, F Cappuzzo, E Felip, FH Blackhall, DB Costa, DW Kim, ...
J Clin Oncol 34 (24), 2858-2865, 2016
|Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC)|
DR Camidge, Y Bang, EL Kwak, AT Shaw, AJ Iafrate, RG Maki, ...
J Clin Oncol 29 (Suppl 15), 2501, 2011